Short Stature and Pubertal Delay in Male Adolescents With Cystic Fibrosis: Androgen Treatment

Christopher Landon, Ron G. Rosenfeld

Research output: Contribution to journalArticle

65 Scopus citations

Abstract

We evaluated the growth rate and pubertal status of 54 adolescent and young adult men with cystic fibrosis and assessed the efficacy of short-term androgen therapy in promoting growth and pubertal development. Thirty-nine percent were below the fifth percentile in height and 8/28 between the ages of 14 and 18 had delays in pubertal development. Five male adolescents aged 13 years 8 months to 18 years 3 months were treated with testosterone and their conditions were prospectively evaluated. Growth rate increased from an entry mean of 2.2 cm/yr to 7.2 cm/yr (3 to 10 cm/yr). We conclude that a brief course of testosterone appears to be a safe, effective means of improving growth rate in male adolescents with cystic fibrosis with delay of puberty.

Original languageEnglish (US)
Pages (from-to)388-391
Number of pages4
JournalAmerican Journal of Diseases of Children
Volume138
Issue number4
DOIs
StatePublished - Apr 1984

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Short Stature and Pubertal Delay in Male Adolescents With Cystic Fibrosis: Androgen Treatment'. Together they form a unique fingerprint.

  • Cite this